8,751
Total Claims
$1.4M
Drug Cost
682
Beneficiaries
$2,087
Cost/Patient
Peer Comparison vs. 110,156 Internal Medicine providers
+48%
Cost per patient vs peers
$2,087 vs $1,411 avg
+59%
Brand preference vs peers
16.9% vs 10.6% avg
Brand vs Generic
83% generic
Brand: 1,433 claims · $1.2M
Generic: 7,066 claims · $180K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 89 | $153K |
| Sitagliptin Phosphate | 124 | $152K |
| Dapagliflozin Propanediol | 94 | $125K |
| Empagliflozin | 81 | $101K |
| Linaclotide | 55 | $61K |
| Denosumab | 35 | $60K |
| Tirzepatide | 41 | $58K |
| Insulin Glargine,hum.Rec.Anlog | 71 | $45K |
| Apixaban | 30 | $34K |
| Linagliptin | 32 | $31K |
| Insulin Degludec | 22 | $28K |
| Insulin Lispro | 35 | $27K |
| Insulin Aspart | 39 | $24K |
| Insulin Glargine,hum.Rec.Anlog | 52 | $23K |
| Semaglutide | 18 | $21K |
Prescribing Profile
Patient Profile
74
Avg Age
59%
Female
1.48
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data